Related Experiment Video

Updated: May 23, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

CA916798 regulates multidrug resistance of lung cancer cells

Hai-Jing Wang1, He-Ping Yang, Xiang-Dong Zhou

  • 1Department of Respiratory Diseases, Third Military Medical University, Chongqing, China.

Asian Pacific Journal of Cancer Prevention : APJCP
|April 5, 2012
PubMed
Abstract

Insights

The gene CA916798 promotes multidrug resistance (MDR) in lung cancer cells, potentially offering a new therapeutic target. Its expression influences chemotherapy response, impacting cell growth and apoptosis in lung adenocarcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multidrug resistance (MDR) is a major challenge in lung cancer chemotherapy.
  • Identifying genes that mediate MDR is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the role of CA916798, a gene upregulated in cisplatin (CDDP)-resistant lung cancer cells, in mediating MDR.
  • To characterize the functional significance of CA916798 in lung adenocarcinoma cells.

Main Methods:

  • CA916798 was overexpressed in H446 cells and knocked down in A549/CDDP cells.
  • Gene expression was confirmed using real-time PCR, Western immunoblotting, and immunocytochemistry.
  • Effects on cellular growth, apoptosis, and cell cycle progression were analyzed.

Main Results:

  • Overexpression of CA916798 enhanced resistance to multiple chemotherapeutic agents.
  • Reduction of CA916798 decreased resistance in CDDP-resistant lung cancer cells.
  • CA916798 was found to regulate CDDP-induced cell growth, apoptosis, and cell cycle progression.

Conclusions:

  • CA916798 plays a significant role in mediating multidrug resistance in lung cancer.
  • CA916798 represents a potential novel therapeutic target for overcoming MDR in lung cancer therapy.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...